This article reviews the evidence from randomized, placebo‐controlled trials and meta‐
analyses of pharmacological treatments of the following anxiety disorders: generalized …

Importance Anxiety disorders have a lifetime prevalence of approximately 34% in the US,
are often chronic, and significantly impair quality of life and functioning. Observations …

Given the enormous contribution of anxiety disorders to the burden of disease, it is key to
optimize their prevention and treatment. In this critical review we assess advances in the …

Anxiety disorders are the most prevalent psychiatric disorders. There is a high comorbidity
between anxiety (especially generalized anxiety disorders or panic disorders) and …

Anxiety disorders, including panic disorder/agoraphobia (PDA), generalized anxiety
disorder (GAD), social anxiety disorder (SAD), and others, are the most prevalent mental …

Anxiety disorders are the most prevalent psychiatric disorders and a leading cause of
disability. While there continues to be expansive research in posttraumatic stress disorder …

Anxiety disorders, as a group, are among the most common mental health conditions and
frequently cause significant functional impairment. Both psychotherapeutic and …

Anxiety disorders affect one-eighth of the total population worldwide, and have become a
very important area of research interest in psychopharmacology. People with anxiety …

Background We aimed to examine the efficacy of selective serotonin reuptake inhibitors
(SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) for anxiety disorders …

Objective: Generalized anxiety disorder (GAD) is common, chronic, and debilitating.
Treatment with benzodiazepines and newer antidepressants is often inadequate. This article …